Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-((((1r)-1-(3-((e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropaneacetic Acid
2. Mk 0476
3. Mk-0476
4. Montelukast
5. Singulair
6. Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
1. 151767-02-1
2. Singulair
3. Montair
4. Montelukast Sodium Salt
5. Montelukast Sodium [usan]
6. Montelukast (sodium)
7. Mk-476
8. Mk-0476
9. Montelukast Na
10. Montelukast (as Sodium)
11. Montelukast Monosodium Salt
12. U1o3j18sfl
13. Chebi:6993
14. Sodium (r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
15. 151767-02-1 (sodium)
16. Singular
17. Nsc-759107
18. Dsstox_cid_26450
19. Dsstox_rid_81624
20. Dsstox_gsid_46450
21. Cyclopropaneacetic Acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Sodium Salt, (r-(e))-
22. Kokast
23. Mls001304727
24. Sodium (r,e)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetate
25. Cas-151767-02-1
26. Cyclopropaneacetic Acid, 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, Sodium Salt (1:1)
27. Smr000469188
28. Sodium;2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate
29. Mk 476
30. Unii-u1o3j18sfl
31. Mk 0476
32. Kipres
33. Lukasm
34. Mfcd00931431
35. Singulair (tn)
36. Cpd000469188
37. Ncgc00164568-01
38. Montelukast Sodium- Bio-x
39. Schembl9414
40. Schembl9415
41. Mls001424198
42. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
43. Chembl1200681
44. Dtxsid8046450
45. Montelukast Sodium [jan]
46. Montelukast Sodium (jp17/usp)
47. Hms2051f18
48. Hms2235h19
49. Hms3885d11
50. Montelukast Sodium [vandf]
51. Montelukast Sodium [mart.]
52. Act06295
53. Montelukast Sodium [usp-rs]
54. Montelukast Sodium [who-dd]
55. Tox21_112197
56. Mk0476
57. S4211
58. Akos015833416
59. Akos032949734
60. Tox21_112197_1
61. Am62787
62. Bcp9000959
63. Ccg-101049
64. Cs-0548
65. Ks-1087
66. Nc00299
67. Nsc 759107
68. Montelukast Monosodium Salt [mi]
69. Montelukast Sodium [orange Book]
70. Montelukast Sodium [ep Monograph]
71. Ncgc00164568-04
72. Bm164606
73. Cyclopropaneacetic Acid, 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Monosodium Salt
74. Hy-13315
75. Montelukast Sodium [usp Monograph]
76. M2340
77. Sw197679-2
78. 2-[1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]thio]methyl]cyclopropyl]acetate; Sodium
79. D00529
80. J-008841
81. J-522711
82. L-706631
83. Q27107384
84. 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic Acid Monosodium Salt
85. 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic Acid Sodium Salt
86. 1-[[[(r)-1-[3-[2-(7-chloro-2-quinolyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-1-cyclopropaneacetic Acid Sodium Salt
87. Cyclopropaneacetic Acid,1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-,sodium Salt
88. Sodium {1-[({(1r)-1-{3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetate
89. Sodium 1-((((r)-m -((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
90. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-.alpha.-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
91. Sodium 1-[[[(1r)-1-[3-[(1e)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate
92. Sodium 2-(1-((((r)-1-(3-((e)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetate
93. Sodium(r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
| Molecular Weight | 608.2 g/mol |
|---|---|
| Molecular Formula | C35H35ClNNaO3S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 12 |
| Exact Mass | 607.1923871 g/mol |
| Monoisotopic Mass | 607.1923871 g/mol |
| Topological Polar Surface Area | 98.6 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 898 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 2 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
| 3 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 4 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
Asthma
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
Cytochrome P-450 CYP1A2 Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inducers.)
Leukotriene Antagonists
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
88
PharmaCompass offers a list of Montelukast Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Montelukast Sodium manufacturer or Montelukast Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Montelukast Sodium manufacturer or Montelukast Sodium supplier.
PharmaCompass also assists you with knowing the Montelukast Sodium API Price utilized in the formulation of products. Montelukast Sodium API Price is not always fixed or binding as the Montelukast Sodium Price is obtained through a variety of data sources. The Montelukast Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Montelukast sodium salt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Montelukast sodium salt, including repackagers and relabelers. The FDA regulates Montelukast sodium salt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Montelukast sodium salt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Montelukast sodium salt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Montelukast sodium salt supplier is an individual or a company that provides Montelukast sodium salt active pharmaceutical ingredient (API) or Montelukast sodium salt finished formulations upon request. The Montelukast sodium salt suppliers may include Montelukast sodium salt API manufacturers, exporters, distributors and traders.
click here to find a list of Montelukast sodium salt suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Montelukast sodium salt DMF (Drug Master File) is a document detailing the whole manufacturing process of Montelukast sodium salt active pharmaceutical ingredient (API) in detail. Different forms of Montelukast sodium salt DMFs exist exist since differing nations have different regulations, such as Montelukast sodium salt USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Montelukast sodium salt DMF submitted to regulatory agencies in the US is known as a USDMF. Montelukast sodium salt USDMF includes data on Montelukast sodium salt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Montelukast sodium salt USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Montelukast sodium salt suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Montelukast sodium salt Drug Master File in Japan (Montelukast sodium salt JDMF) empowers Montelukast sodium salt API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Montelukast sodium salt JDMF during the approval evaluation for pharmaceutical products. At the time of Montelukast sodium salt JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Montelukast sodium salt suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Montelukast sodium salt Drug Master File in Korea (Montelukast sodium salt KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Montelukast sodium salt. The MFDS reviews the Montelukast sodium salt KDMF as part of the drug registration process and uses the information provided in the Montelukast sodium salt KDMF to evaluate the safety and efficacy of the drug.
After submitting a Montelukast sodium salt KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Montelukast sodium salt API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Montelukast sodium salt suppliers with KDMF on PharmaCompass.
A Montelukast sodium salt CEP of the European Pharmacopoeia monograph is often referred to as a Montelukast sodium salt Certificate of Suitability (COS). The purpose of a Montelukast sodium salt CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Montelukast sodium salt EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Montelukast sodium salt to their clients by showing that a Montelukast sodium salt CEP has been issued for it. The manufacturer submits a Montelukast sodium salt CEP (COS) as part of the market authorization procedure, and it takes on the role of a Montelukast sodium salt CEP holder for the record. Additionally, the data presented in the Montelukast sodium salt CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Montelukast sodium salt DMF.
A Montelukast sodium salt CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Montelukast sodium salt CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Montelukast sodium salt suppliers with CEP (COS) on PharmaCompass.
A Montelukast sodium salt written confirmation (Montelukast sodium salt WC) is an official document issued by a regulatory agency to a Montelukast sodium salt manufacturer, verifying that the manufacturing facility of a Montelukast sodium salt active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Montelukast sodium salt APIs or Montelukast sodium salt finished pharmaceutical products to another nation, regulatory agencies frequently require a Montelukast sodium salt WC (written confirmation) as part of the regulatory process.
click here to find a list of Montelukast sodium salt suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Montelukast sodium salt as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Montelukast sodium salt API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Montelukast sodium salt as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Montelukast sodium salt and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Montelukast sodium salt NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Montelukast sodium salt suppliers with NDC on PharmaCompass.
Montelukast sodium salt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Montelukast sodium salt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Montelukast sodium salt GMP manufacturer or Montelukast sodium salt GMP API supplier for your needs.
A Montelukast sodium salt CoA (Certificate of Analysis) is a formal document that attests to Montelukast sodium salt's compliance with Montelukast sodium salt specifications and serves as a tool for batch-level quality control.
Montelukast sodium salt CoA mostly includes findings from lab analyses of a specific batch. For each Montelukast sodium salt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Montelukast sodium salt may be tested according to a variety of international standards, such as European Pharmacopoeia (Montelukast sodium salt EP), Montelukast sodium salt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Montelukast sodium salt USP).